Skip to content

Spec. 0004 — ongoing

Everything the agent left behind

It proposes peptides nobody asked for, then spends the rest of the run trying to kill them. Eight gates, each with a verdict and a confidence, each one able to end the candidate. What survives is published — and so is what didn't.

Fig. 1 — candidate under scanα-helix, 26 residues

Candidate

RSD-4820

Scanning

ALA · 01/26

Fold ΔG

7.2 kcal/mol

Live
Runs on record
9
Cleared all eight
6
Liabilities flagged
22
Reasoning withheld
None
01  /  The stackRun it →

Eight ways to be wrong

A candidate is not scored, it is interrogated. Every gate is a place the run can end, and the gate that ends it says so in plain language rather than dropping a number.

Fig. 2 — one candidate, eight gatesEight abandoned · one residue
  1. 01

    Target definition

    Receptor, pathway, therapeutic rationale

    Ends onA mechanism nobody can name

  2. 02

    Sequence design

    Residues, modifications, analogue lineage

    Ends onMotifs borrowed without reason

  3. 03

    Structure & conformation

    Secondary structure, folding, cyclisation

    Ends onA fold that will not hold

  4. 04

    Binding affinity

    Predicted potency and selectivity

    Ends onPotency bought with selectivity

  5. 05

    Stability & half-life

    Protease exposure, plasma persistence

    Ends onMinutes of plasma survival

  6. 06

    Off-target risk

    Cross-reactivity and safety flags

    Ends onReceptors hit by accident

  7. 07

    Synthesis feasibility

    SPPS route, yield, purification burden

    Ends onRoutes no lab would run

  8. 08

    Wet-lab handoff

    Assays to run, success criteria

    Ends onA plan with no falsifier

02  /  Method

How a run actually goes

There is no ranking model and no hidden score. The agent reasons in text, in order, and the text is the product.

  1. 01

    A brief goes in

    One or two sentences describing a problem worth solving — a liability to engineer around, a receptor to reach, a half-life to beat. No structure required.

  2. 02

    The agent traverses

    It works the gates in order and cannot skip. Later gates read the earlier ones, so a weak sequence design is still hanging over the run by the time synthesis is assessed.

  3. 03

    Verdicts land in the open

    Pass, flag or fail, each with a stated confidence and the reasoning that produced it. Text streams as it is written — nothing is assembled behind a spinner.

  4. 04

    The run is written down

    Every completed traverse is appended to a shared journal with its verdicts, model and timing. Runs are not curated after the fact.

03  /  JournalEvery run →

The most recent traverses

Exactly as they landed. Anyone can start a run, and everyone sees the same log.

  1. 2d agoclearedanthropic/claude-sonnet-4.5

    A GLP-1 analogue with reduced nausea liability at equivalent weight-loss efficacy

    GLP-1R (glucagon-like peptide-1 receptor) is well-validated as a weight-loss target, with semaglutide and tirzepatide demonstrating 15-20% body weight reduction in phase 3 trials. The receptor is a class B GPCR expressed in pancreatic beta cells, CNS appetite centers (hypothalamus, area postrema), and critically the br

    5 pass · 3 flag · 0 fail82.1s
  2. 2d agoclearedanthropic/claude-sonnet-4.5

    A GLP-1 analogue with reduced nausea liability at equivalent weight-loss efficacy

    Reducing area postrema engagement while preserving hypothalamic signalling is the central tension. Biased agonism at GLP-1R toward Gs over beta-arrestin is the most promising handle, though the separation achieved in published analogues is modest.

    6 pass · 2 flag · 0 fail38.4s
  3. 2d agoheldanthropic/claude-sonnet-4.5

    A BPC-157 variant with improved plasma stability for systemic tendon repair

    The pentadecapeptide has no defined tertiary structure, which is precisely why stabilising it is hard — there is no fold to rigidify. N-terminal acetylation and D-amino acid substitution at positions 4 and 11 are the obvious first passes.

    4 pass · 3 flag · 1 fail33.1s
  4. 3d agoclearedopenai/gpt-4o-mini

    Evaluate MOTS-C 10mg as a research candidate.

    MOTS-c is encoded in the mitochondrial 12S rRNA region rather than the nucleus, which makes it unusual among signalling peptides. Reported AMPK activation is consistent across rodent work but human data remains thin.

    6 pass · 2 flag · 0 fail21.8s
04  /  Disclosure

The failures are the point

A discovery process you only see the wins from tells you nothing about how it decides. The whole reason the trail is public is so the bad calls are countable.

Analytical chemistry instruments in a laboratory
Fig. 3 — the instruments we do not have

The failed runs stay up

A journal that only shows candidates which cleared is a brochure. Every traverse is appended the moment it completes, including the ones where gate three ended it, and nothing is deleted afterwards.

0

runs removed

Confidence is stated, not implied

Each verdict carries a number the agent had to commit to. Low confidence on a pass is a different object from high confidence on a pass, and the journal keeps both.

verdicts per run

This is triage, not evidence

The agent has no lab. It runs no simulations and reasons only over what it was trained on, which means it will state wrong numbers with total composure. Treat every figure as a hypothesis with an experiment attached.

0

assays performed

05  /  IndexAll 62

What made it out

Compounds that cleared the stack and have a certificate attached. The index is the residue of the research, not the reason for it.

06  /  Questionslab@residue.bio

The things people ask

Still unsure? Write to the lab and a person will answer.

The console is open

Give it something hard

Describe a liability worth engineering around and watch the agent try to talk itself out of the answer.